AR085163A1 - Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos - Google Patents
Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usosInfo
- Publication number
- AR085163A1 AR085163A1 ARP120100455A ARP120100455A AR085163A1 AR 085163 A1 AR085163 A1 AR 085163A1 AR P120100455 A ARP120100455 A AR P120100455A AR P120100455 A ARP120100455 A AR P120100455A AR 085163 A1 AR085163 A1 AR 085163A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- amino
- heteroaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen 4-amino-2-butenamidas que tienen actividad farmacológica, composiciones farmacéuticas que las contienen, y métodos para el tratamiento de enfermedades mediadas por la enzima catepsina C.Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: cada uno de R1 y R2 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, cicloalquenilo C5-8, bicicloalquilo C6-10 heterocicloalquilo, cicloalquil C3-8-alquilo C1-6, cicloalquenil C5-8-alquilo C1-6, heterocicloalquil-alquilo C1-6, arilo, heteroarilo, aril-alquilo C1-6 y heteroarilalquilo C1-6; donde cualquier alquilo C1-8, alquenilo C2-8 o alquinilo C2-8 está opcionalmente sustituido de una a tres veces, independientemente, por CF3, ciano, -CO2-alquilo C1-4, -CONH-alquilo C1-4, -CON-alquil C1-4-alquilo C1-4, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4, -SO2N-alquil C1-4-alquilo C1-4, amino, alquil-C1-4amino, (alquil C1-4)(alquil C1-4)amino, hidroxilo o alcoxi C1-4; y donde cualquier grupo cicloalquilo, cicloalquenilo, bicicloalquilo o heterocicloalquilo está opcionalmente sustituido de una a tres veces, independientemente, por alquilo C1-4, haloalquilo C1-4, ciano, -CO2-alquilo C1-4, -CONH-alquilo C1-4, -CON-alquil C1-4-alquilo C1-4, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4 -SO2N-alquil C1-4-alquilo C1-4, amino, alquil C1-4 amino, (alquil C1-4)(alquil C1-4)amino, hidroxilo, alcoxi C1-4, arilo o aril-alquilo C1-4, donde el resto arilo de dicho arilo o aril-alquilo C1-4 está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, -CF3, alquilo C1-4, hidroxilo o alcoxi C1-4; y donde cualquier grupo arilo o heteroarilo está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, alquilo C1-6, cicloalquilo C3-6, cicloalquenilo C5-6, haloalquilo C1-6, ciano, -CO2-alquilo C1-4, -CONH-alquilo C1-4, -CON-alquil C1-4-alquilo C1-4, -SO2-alquilo C1-4, -SO2NH-alquilo C1-4, -SO2N-alquil C1-4-alquilo C1-4, amino, alquil C1-4 amino, (alquil C1-4)(alquil C1-4)amino, hidroxilo, alcoxi C1-4, alquil C1-4tio-, arilo, heteroarilo, aril-alquilo C1-4 o heteroaril-alquilo C1-4; donde cualquier resto arilo o heteroarilo de dicho arilo, heteroarilo, aril-alquilo C1-4 o heteroaril-alquilo C1-4 está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, -CF3, alquilo C1-4, hidroxilo o alcoxi C1-4; y donde cualquier cicloalquilo C3-6 está opcionalmente sustituido de una a tres veces, independientemente, por alquilo C1-4, arilo o heteroarilo; donde dicho arilo o heteroarilo está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, -CF3, alquilo C1-4, hidroxilo o alcoxi C1-4; o R1 y R2, tomados junto con el nitrógeno al que están unidos, representan un anillo saturado o insaturado de 5 a 7 miembros que contiene opcionalmente otro heteroátomo que es oxígeno, nitrógeno o azufre, donde dicho anillo está opcionalmente condensado con un anillo cicloalquilo C3-8, heterocicloalquilo, arilo o heteroarilo; o R1 y R2, tomados junto con el nitrógeno al que están unidos, representan un sistema de anillos bicíclico, puenteado, de 6 a 10 miembros opcionalmente condensado con un anillo cicloalquilo C3-8, heterocicloalquilo, arilo o heteroarilo; y R3 es hidrógeno, alquilo C1-8, haloalquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-6, cicloalquenilo C5-6, cicloalquil C3-6-alquilo C1-4, cicloalquenil C5-6-alquilo C1-4 o aril-alquilo C1-4, donde el resto arilo del aril-alquilo C1-4 está opcionalmente sustituido de una a tres veces, independientemente, por halógeno, alquilo C1-4 ó -CF3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441840P | 2011-02-11 | 2011-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085163A1 true AR085163A1 (es) | 2013-09-11 |
Family
ID=46638952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100455A AR085163A1 (es) | 2011-02-11 | 2012-02-10 | Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8841463B2 (es) |
| EP (1) | EP2672821B9 (es) |
| JP (1) | JP5931929B2 (es) |
| KR (1) | KR20140048857A (es) |
| CN (1) | CN103491777B (es) |
| AR (1) | AR085163A1 (es) |
| AU (1) | AU2012214405B2 (es) |
| BR (1) | BR112013020510A2 (es) |
| CA (1) | CA2827157A1 (es) |
| CL (1) | CL2013002325A1 (es) |
| CO (1) | CO6741219A2 (es) |
| DO (1) | DOP2013000182A (es) |
| EA (1) | EA023168B1 (es) |
| ES (1) | ES2583091T3 (es) |
| IL (1) | IL227814A0 (es) |
| MA (1) | MA34961B1 (es) |
| MX (1) | MX2013009279A (es) |
| PE (1) | PE20140999A1 (es) |
| PH (1) | PH12013501665A1 (es) |
| SG (1) | SG192669A1 (es) |
| TW (1) | TW201302736A (es) |
| UY (1) | UY33905A (es) |
| WO (1) | WO2012109415A1 (es) |
| ZA (1) | ZA201306074B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| NO2699580T3 (es) | 2014-01-24 | 2018-02-24 | ||
| CN109153642B (zh) * | 2016-02-12 | 2022-05-17 | 法玛西斯有限公司 | 赖氨酰氧化酶的吲哚及氮杂吲哚卤化烯丙胺衍生物抑制剂及其用途 |
| CA3257803A1 (en) | 2022-06-13 | 2025-04-04 | Alivexis, Inc. | AZACYCLOLAKYL CARBONYL CYCLIC AMINE COMPOUND |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
| CN1240355A (zh) * | 1996-05-01 | 2000-01-05 | 伊莱利利公司 | 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途 |
| US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| US6214799B1 (en) | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
| WO2002048097A1 (en) * | 2000-12-12 | 2002-06-20 | Corvas International, Inc. | Compounds, compositions and methods for treatment of parasitic infections |
| US8114871B2 (en) * | 2007-04-12 | 2012-02-14 | Pfizer Inc. | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives |
| KR20120034639A (ko) * | 2009-05-07 | 2012-04-12 | 아스트라제네카 아베 | 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750 |
| UY32827A (es) | 2009-08-12 | 2011-02-28 | Glaxo Group Ltd | Inhibidores de catepsina c |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
-
2012
- 2012-02-09 AU AU2012214405A patent/AU2012214405B2/en not_active Ceased
- 2012-02-09 UY UY0001033905A patent/UY33905A/es unknown
- 2012-02-09 ES ES12744272.1T patent/ES2583091T3/es active Active
- 2012-02-09 EA EA201391155A patent/EA023168B1/ru not_active IP Right Cessation
- 2012-02-09 MX MX2013009279A patent/MX2013009279A/es not_active Application Discontinuation
- 2012-02-09 US US13/984,061 patent/US8841463B2/en not_active Expired - Fee Related
- 2012-02-09 TW TW101104141A patent/TW201302736A/zh unknown
- 2012-02-09 PE PE2013001836A patent/PE20140999A1/es not_active Application Discontinuation
- 2012-02-09 JP JP2013553538A patent/JP5931929B2/ja not_active Expired - Fee Related
- 2012-02-09 KR KR1020137023618A patent/KR20140048857A/ko not_active Ceased
- 2012-02-09 BR BR112013020510A patent/BR112013020510A2/pt not_active IP Right Cessation
- 2012-02-09 WO PCT/US2012/024428 patent/WO2012109415A1/en not_active Ceased
- 2012-02-09 EP EP12744272.1A patent/EP2672821B9/en active Active
- 2012-02-09 CN CN201280017698.7A patent/CN103491777B/zh not_active Expired - Fee Related
- 2012-02-09 SG SG2013060165A patent/SG192669A1/en unknown
- 2012-02-09 MA MA36229A patent/MA34961B1/fr unknown
- 2012-02-09 PH PH1/2013/501665A patent/PH12013501665A1/en unknown
- 2012-02-09 CA CA2827157A patent/CA2827157A1/en not_active Abandoned
- 2012-02-10 AR ARP120100455A patent/AR085163A1/es unknown
-
2013
- 2013-08-05 IL IL227814A patent/IL227814A0/en unknown
- 2013-08-09 CL CL2013002325A patent/CL2013002325A1/es unknown
- 2013-08-09 CO CO13190045A patent/CO6741219A2/es unknown
- 2013-08-09 DO DO2013000182A patent/DOP2013000182A/es unknown
- 2013-08-13 ZA ZA2013/06074A patent/ZA201306074B/en unknown
-
2014
- 2014-08-21 US US14/464,734 patent/US9187461B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| PE20141358A1 (es) | Polimorfos de inhibidores de cinasas | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| UY33044A (es) | Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| UY32077A (es) | Inhibidores de quinasa tipo polo | |
| AR085163A1 (es) | Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos | |
| MX376743B (es) | Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| CO6761373A2 (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas | |
| MX2019006920A (es) | Derivados de la espiropiperidina. | |
| AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
| PE20141391A1 (es) | Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |